3.245

0.15% -0.005

Atea Pharmaceuticals Inc (AVIR)

Overview News Price History Option Chain Financials Discussions Forecast

Atea Pharmaceuticals Inc stock is traded at $3.245, with a volume of 158.01K. It is down -0.15% in the last 24 hours and up +11.90% over the past month. Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Previous Close:

$3.25

Open:

$3.22

24h Volume:

158.01K

Relative Volume:

0.45

Market Cap:

$257.52M

Revenue:

$351.37M

Net Income/Loss:

$-174.01M

P/E Ratio:

-1.5676

EPS:

-2.07

Net Cash Flow:

$-126.94M

1W Performance:

-0.15%

1M Performance:

+11.90%

6M Performance:

+8.89%

1Y Performance:

-1.37%

1-Day Range:

$3.15

$3.26

1-Week Range:

$3.15

$3.335

52-Week Range:

$2.455

$4.02

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name

Atea Pharmaceuticals Inc

Sector

Healthcare (1139)

Industry

Biotechnology (635)

Phone

857-204-8109

Address

225 FRANKLIN STREET, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

AVIR's Discussions on Twitter

Compare AVIR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVIR Atea Pharmaceuticals Inc	3.245	257.91M	351.37M	-174.01M	-126.94M	-2.07
VRTX Vertex Pharmaceuticals Inc	425.74	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.28	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	431.20	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	825.82	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.06	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-13-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	JP Morgan	Overweight
Nov-24-20	Initiated	Morgan Stanley	Overweight
Nov-24-20	Initiated	William Blair	Outperform

View All

Atea Pharmaceuticals Inc Stock (AVIR) Latest News

08:03 AM

Is Atea Pharmaceuticals Inc. stock reversal real or fakeJuly 2025 EndofMonth & Verified Technical Signals - newser.com

08:03 AM

06:21 AM

Backtesting results for Atea Pharmaceuticals Inc. trading strategiesEarnings Beat & Risk Managed Investment Entry Signals - newser.com

06:21 AM

04:40 AM

Is a relief rally coming for Atea Pharmaceuticals Inc. holdersJuly 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com

04:40 AM

03:13 AM

Live market analysis of Atea Pharmaceuticals Inc.July 2025 Fed Impact & Community Shared Stock Ideas - newser.com

03:13 AM

Nov 02, 2025

Is Atea Pharmaceuticals Inc. still worth holding after the dipBuy Signal & Consistent Return Investment Signals - newser.com

Nov 02, 2025

Atea Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Update & Verified Momentum Watchlists - newser.com

Nov 02, 2025

Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataJuly 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com

Nov 02, 2025

Is Atea Pharmaceuticals Inc. stock cheap at current valuation2025 Market Overview & High Accuracy Swing Entry Alerts - newser.com

Nov 02, 2025

Nov 01, 2025